CLINICAL PERFORMANCE
Outperforming TMB and PD-L1 on what matters most
“Who NOT to treat” is the question oncologists need answered, because immunotherapy costs $100K–$200K+ per patient per year and carries life-threatening side effects. Predicting Non-responders is the most clinically important metric. GMDx IFP substantially outperforms TMB and PD-L1.
* PD-L1 represents the mean of 9 published NSCLC clinical trials (Range:30-64%)
** TMB represents the mean of 10 published NSCLC clinical trials (Range:54-68%)
MULTI-CENTRE VALIDATION
Three independent response studies, plus leading centres
PANEL DATA
Tempus xT panel
n=263 validation
81%
Accurately predicted non-responders
PUBLIC DATA
Published Exomes
n=167 validation
84%
Accurately predicted non-responders
REAL-WORLD DATA
Tempus Exomes
n=30 validation
91%
Accurately predicted non-responders
COLLABORATING CENTRES
Alfred Hospital
University of Kansas Medical Center
Foundational performance: Lindley 2016 (Cancer Medicine), 95% sensitivity and 90% specificity in HGSOC. Supporting data: Mamrot 2021 (Oncotarget); Lindley 2025 (IJMS).
Monash University
Melanoma Research Victoria
CGFL · France
City of Hope · USA
Garvan Institute of Medical Research
Gustave Roussy · France
Omico
Samsung Medical Center · South Korea